Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Explore this paper's citation graph
Summary
The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
- Type
- article
- Published
- 2020-01-01
- Cited by
- 2,437
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W2984359187
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:207890745
Keywords
Pembrolizumab, Medicine, Microsatellite instability, Cancer, Internal medicine
References
- Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
- The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
- Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis
- Comprehensive Molecular Characterization of Human Colon and Rectal Cancer
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
- PD-1 blockade in tumors with mismatch repair deficiency.
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade
- Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study
- Landscape of Microsatellite Instability Across 39 Cancer Types
- First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
- Precision medicine becomes reality—tumor type-agnostic therapy
- Pan-cancer microsatellite instability to predict for presence of Lynch syndrome.
- New windows open for immunotherapy in lung cancer
- Lynch syndrome – cancer pathways, heterogeneity and immune escape
- Association of PD-L1 expression with prognosis among patients with 10 select cancers.
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
- A molecular portrait of microsatellite instability across multiple cancers
Cited by
- Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
- Advances and challenges in immunotherapy of small cell lung cancer
- Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- MSI-H: a truly agnostic biomarker?
- Adjuvant chemotherapy in endometrial cancer
- Precision Medicine in Soft Tissue Sarcoma Treatment
- From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
- Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
- Biomarkers for Hepatobiliary Cancers
- Recent advances in the treatment of pancreatic cancer
- Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
- Molecular targeted therapies: ready for "prime time" in biliary tract cancer.
- Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
- New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- Immuntherapeutische Therapieansätze – ein Überblick
- OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
- Periampulläre Tumoren: Therapie und Prognose
- Immunotherapy for pancreatic cancer: A 2020 update.
Related papers
- Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method.
- Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
- Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines
- High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma.
- Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.
- Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
- DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome
- Abstract IA008: Mismatch repair deficiency and survival in stage I endometrial cancer
- Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus‐associated adenocarcinoma
- Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer